Evidence map›Paper›PMID 32955946›Full record

ReviewExpert opinion on pharmacotherapy2021

Pharmacotherapeutic options for kidney disease in HIV positive patients.

Anam Tariq, Hannah Kim, Hashim Abbas, Gregory M Lucas, Mohamed G Atta

Erratum issuedOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on pharmacotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anam TariqDivision of Nephrology, Johns Hopkins University , Baltimore, MD, US.ORCID https://orcid.org/0000-0002-0728-8436
Hannah KimDivision of Pediatric Nephrology, Johns Hopkins University , Baltimore, MD, US.
Hashim AbbasDivision of Nephrology, Johns Hopkins University , Baltimore, MD, US.
Gregory M LucasDivision of Infectious Disease, Johns Hopkins University , Baltimore, MD, US.ORCID https://orcid.org/0000-0002-3013-4339
Mohamed G AttaDivision of Nephrology, Johns Hopkins University , Baltimore, MD, US.
Johns Hopkins University · US

Funding

VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHYP01DK056492 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI KLOTMAN, PAUL EVAN · 1999 to 2021
$27.8M
Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Hopkins Clinical CenterU01DK061022 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI APPEL, LAWRENCE JOHN · 2001 to 2025
$15.7M
RENAL DISEASE EPIDEMIOLOGY TRAINING GRANTT32DK007732 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CREWS, DEIDRA CANDICE · 1995 to 2024
$7.7M
Early-Stage Chronic Kidney Disease in HIV-infected IndividualsR01DA026770 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2010 to 2020
$5.7M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
NIDA NIH HHS K24 DA035684NIDA NIH HHS R01 DA026770NIDDK NIH HHS P01 DK056492NIDDK NIH HHS T32 DK007732NIDDK NIH HHS U01 DK061022
6 · The paper itself

Abstract

introductionSince the developmentof combined antiretroviral therapy (cART), HIV-associated mortality and the incidence of HIV-associated end-stage kidney disease (ESKD) has decreased. However, in the United States, an increase in non-HIV-associated kidney diseases within the HIV-positive population is expected. AREAS COVERED: In this review, the authors highlight the risk factors for kidney disease within an HIV-positive population and provide the current recommendations for risk stratification and for the monitoring of its progression to chronic kidney disease (CKD), as well as, treatment. The article is based on literature searches using PubMed, Medline and SCOPUS. EXPERT OPINION: The authors recommend clinicians (1) be aware of early cART initiation to prevent and treat HIV-associated kidney diseases, (2) be aware of cART side effects and discriminate those that may become more nephrotoxic than others and require dose-adjustment in the setting of eGFR ≤ 30ml/min/1.73m

Indexed as

Disease ProgressionGlomerular Filtration RateHIV InfectionsHumansKidney Failure, ChronicKidney TransplantationRenal Insufficiency, ChronicRisk FactorsUnited Statesantiretroviral medicationsAPOL1dialysisHIVHIVANHIVICKnephrotoxicity

Identifiers

PMID32955946
PMCPMC7855280
OpenAlexW3087600258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.